ISSN: 0443-511
e-ISSN: 2448-5667
Usuario/a
Idioma
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)
Tamaño de fuente

Open Journal Systems

Eritema flagelado secundario a bleomicina: reporte de un caso clínico de evolución favorable / Flagellate erythema secondary to bleomycin: case report with favorable outcome

Ricardo Leal-León, Antonio Tirado-Motel, Marian Escribano-Ponce, Vanessa González-Ruiz, María Teresa de Jesús Vega-González

Resumen


Resumen

Introducción: el eritema flagelado (EF) es una dermatosis de origen multifactorial, frecuentemente relacionada con el uso de ciertos fármacos. Se presenta en hasta 20% de los pacientes tratados con bleomicina. La acumulación del fármaco en la piel quizás se deba a la carencia de la enzima hidrolasa bleomicina. Se manifiesta con una dermatosis diseminada, predominante en tronco y extremidades superiores, caracterizada por máculas eritemato-hiperpigmentadas de tamaño variable, con disposición lineal y aspecto de "latigazos", asociadas a prurito intenso. El manejo se centra en aliviar el prurito con antihistamínicos y esteroides tópicos, aunque suspender la bleomicina es fundamental para la resolución completa.

Caso clínico: mujer de 19 años, con antecedente de disgerminoma de ovario izquierdo estadio IIIB, en tratamiento con quimioterapia combinada (bleomicina, etopósido y cisplatino). Tras 3 meses de tratamiento, presentó dermatosis diseminada en cuello y región posterior del tórax, constituida por manchas hiperpigmentadas de color marrón oscuro, con configuración lineal y tamaños variables, asociadas a prurito, sin otros síntomas. Se diagnosticó EF por bleomicina. Se indicó tratamiento con corticoesteroides tópicos de alta potencia. Tras suspender la bleomicina, hubo una desaparición progresiva de la dermatosis hasta su resolución completa.

Conclusión: se debe identificar el EF por bleomicina tempranamente para un manejo adecuado que permita continuar el tratamiento antineoplásico. La suspensión del fármaco debe considerarse cuando se comprometa la calidad de vida del paciente y se equilibre con el control oncológico, lo que optimiza el tratamiento antineoplásico.

 

Abstract

Background: Flagellate erythema (FE) is a multifactorial dermatosis, frecuently related to the the use of certain drugs. It can occur in up to 20% of patients treated with bleomycin. Drug accumulation in the skin can be due to the lack of the enzyme bleomycin hydrolase. It presents as a widespread dermatosis, predominantly affecting the trunk and upper extremities, characterized by erythematous-hyperpigmented macules of variable size, with a linear arrangement and a "whip-like" appearance, associated with intense pruritus. Management focuses on relieving pruritus with antihistamines and topical steroids, although discontinuation of bleomycin is essential for complete resolution.

Case report: A 19-year-old woman with a history of stage IIIB left ovarian dysgerminoma was undergoing combined chemotherapy (bleomycin, etoposide, and cisplatin). After 3 months of treatment, she developed a widespread dermatosis on the neck and posterior thoracic region, consisting of dark brown hyperpigmented spots with a linear configuration and variable sizes, associated with pruritus, without other symptoms. FE due to bleomycin was diagnosed. High-potency topical corticosteroids were prescribed. After discontinuing bleomycin, there was a progressive disappearance of the dermatosis until complete resolution.

Conclusion: The bleomycin-induced FE must be identified early for appropriate management that allows the continuation of antineoplastic treatment. Discontinuation of the drug should be considered when the patient's quality of life is compromised and balanced with oncological control, which optimizes antineoplastic therapy.


Palabras clave


Eritema; Bleomicina; Hiperpigmentación / Erythema; Bleomycin; Hyperpigmentation

Texto completo:

PDF

Referencias


Mavridou A. Flagellate dermatitis in a patient with testicular germ cell neoplasia on bleomycin. Dermatology Reports. 2023;15(1):e9761. doi: 10.4081/dr.2023.9761

Constantinou A, Koutouzis M, Koutouzis T, et al. A closer look at chemotherapy‐induced flagellate dermatitis. Skin Health and Disease. 2022;2(1):e92. doi: 10.1002/ski2.92

Sunigdha S, Kumar A, Gupta S, et al. Bleomycin-Induced Flagellate Dermatitis in Indian Patients with Germ Cell Tumors. Indian Journal of Medical and Paediatric Oncology. 2022;43(1):e1-e5. doi: 10.1055/s-0042-1749394

Lee Y, Kim J, Kim Y, et al. Bleomycin-induced flagellate erythema: A case report and review of the literature. Oncology Letters. 2014;8(6):2615-8. doi: 10.3892/ol.2014.2179

Verma S, Gupta S, Kumar A, et al. Bleomycin-Induced Flagellate Dermatitis: Revisited. Cureus. 2022;14(8):e29221. doi: 10.7759/cureus.29221

Cullingham A, Kost J. A case of bleomycin-induced flagellate dermatitis: A case report. Sage Open Medical Case Reports. 2021;9:2050313X211039476. doi: 10.1177/2050313x211039476

Indrastuti R, Kurniawan A, Sari R, et al. Flagellate dermatitis in bleomycin chemotherapy: a causality? BMJ Case Reports. 2022;15(1):e249704. doi: 10.1136/bcr-2022-249704

Todkill D, Taibjee S, Borg A, et al. Flagellate erythema due to bleomycin. Br J Haematol. 2008;142(6):857. doi: 10.1111/j.1365-2141.2008.07238.x

Tonin F, Vukadinovic M, Jovanovic M, et al. Bleomycin-induced Flagellate Dermatitis: a Case Report. Serbian Journal of Dermatology and Venerology. 2020;12(1):34-7. doi: 10.2478/sjdv-2020-0003

Boppana SM, Vegesana BP. Bleomycin induced flagellate dermatitis: A clinical image. J Clin Images Med Case Rep. 2023;4(12):2746.

Droppelmann M, González C, Araya J, et al. Eritema Flagelado por ingesta de hongos Shiitake: reporte de caso. Revista Chilena de Dermatología. 2018;33(3):162-5. doi: 10.31879/rcderm.v33i3.162

Jannic A, Boulanger N, Dufour C, et al. Flagellate erythema in systemic sclerosis: A case report. JAAD Case Reports. 2018;4(2):144-6. doi: 10.1016/j.jdcr.2017.09.013

Ching A, Wong J, Wong C, et al. Histological Features of Flagellate Erythema. American Journal of Dermatopathology. 2019;41(4):273-8. doi: 10.1097/dad.0000000000001271

Garg A. Bleomycin-induced Flagellate Dermatitis. Indian Journal of Paediatric Dermatology. 2023;24(1):1-3. doi: 10.4103/ijpd.ijpd_97_22

Pereira R, Morbeck A. Flagellate Erythema Secondary to Bleomycin for Non-Seminomatous Testis Tumor. Brazilian Journal of Case Reports. 2021;1(3):86-9. doi: 10.52600/2763-583x.bjcr.2021.1.3.86-89

Sauteur P, Theiler M. Mycoplasma pneumoniae–associated flagellate erythema. JAAD Case Reports. 2020;6(5):467-9. doi: 10.1016/j.jdcr.2020.09.029

Yılmaz U, Zulfaliyeva G, Güzelli AN, et al. Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma. J Chemother. 2024;36(5):403-10. doi: 10.1080/1120009X.2023.2281089

Vegesana K. Bleomycin induced flagellate dermatitis: A clinical image. Journal of Clinical Images and Medical Case Reports. 2023;1(1):1-3. doi: 10.52768/2766-7820/2746

Martinez-Cabrera I, Lopez-Estebaranz JL. Bleomycin-induced flagellate erythema in patients undergoing chemotherapy: Clinical review. Clin Exp Dermatol. 2023;48(2):234-9. doi: 10.1111/ced.15394

Simons MJ, Robinson J, Harris C, et al. Long-term outcomes of chemotherapy-induced dermatologic reactions: A cohort study. J Am Acad Dermatol. 2022;86(5):1075-82. doi: 10.1016/j.jaad.2021.11.022

Thompson RD, Kahn LG. Management strategies for chemotherapy-induced flagellate dermatitis. Int J Dermatol. 2023;62(7):903-10. doi: 10.1111/ijd.16311

Aguilar MT, Vasquez J, Mendoza A. Case report: Severe flagellate erythema after bleomycin treatment in a young adult. BMJ Case Reports. 2021;14(3):e240512. doi: 10.1136/bcr-2020-240512

Yu H, Zhao J, Liu C. Comparative study of flagellate erythema: Drug-induced versus idiopathic causes. Dermatol Ther. 2023;36(1):e15799. doi: 10.1111/dth.15799




DOI: https://doi.org/10.24875/10.5281/zenodo.15178515

Enlaces refback

  • No hay ningún enlace refback.